摘要
目的 探讨丹参注射液 (丹参 )、生脉注射液 (生脉 )及丹参与生脉注射液合用对阻塞性黄疸术后细胞因子及肾功能的影响。方法 将阻塞性黄疸与无黄疸的肝胆外科患者分成 5组。黄疸对照组及无黄疸对照组术后给予一般治疗 ,丹参、生脉及丹参与生脉合用 3个治疗组在阻塞性黄疸术后 1～ 6d ,分别给予丹参、生脉及丹参与生脉合用 ,动态观察血浆内毒素 (LPS) ,肿瘤坏死因子 (TNFα) ,白细胞介素 - 6 ,8(IL - 6 ,IL - 8) ,内皮素 (ET)以及尿转铁蛋白 (UTFR) ,尿白蛋白 (UALB)和尿视黄醇(URBP)。结果 丹参、生脉及丹参与生脉合用治疗组术后 7d与术后 1d相比 ,LPS ,IL - 6、8,ET ,TNFα ,UTFR ,URBP ,UALB明显下降 (P <0 .0 5 ) ,且低于或接近术前水平 ,其中UALB ,URBP与黄疸对照组术后 7d相比也有显著性差异 (P <0 .0 5 )。丹参和生脉合用组术后 7d的ET ,TNFα,IL - 6 ,UALB水平较丹参组明显降低 ,与生脉组相比ET ,TNFα ,IL - 6 ,URBP有显著性差异 (P <0 .0 5 )。结论 丹参注射液、生脉注射液及丹参与生脉注射液合用对阻塞性黄疸患者术后血浆LPS有拮抗作用 ,同时降低其他细胞因子水平 ,从而具有保护肾脏功能的作用 ;
OBJECTIVE To investigate the effects of Shengmai(SM),Salvia Miltiorrhiza(SMa),and Shengmai with Salvia miltiorrhiza(SS) on cytokines and renal function in patients with obstructive jaundice(OJ). METHODS This study included five groups: the OJ patients receiving SMa for 6 days after operation(the SMa group,n=18); the OJ patients receiving SS for 6 days after operation(the SS group,n=15); the OJ patients receiving SM for 6 days after operation; the OJ patients not receiving SS and SM(the OJ group,n=15); the patients with other hepato-biliary disorders(the Non-OJ group,n=15). The levels of ET, LPs, TNFα, IL-6, IL-8 and urine RBP, TFR, ALB were measured one day before the operation and 1, 4, 7 days after the operation,respectively. RESULTS The SM, SMa and SS groups' LPS,TNFα, IL-6, IL-8, ET, RBP, TFR and ALB levels were obviously lower on the 7th day after the operation than those on the first day after the operation(P<0.05). The urine RBP and ALB levels were significantly lower in the SS group than in the OJ group(P<0.05).Furthermore, in the SS group, ET, TNFα, IL-6, UALB or URBP levels were obviously lower on the 7th day after operation than those in the SM and SMa group. CONCLUSION Use of Salvia miltiorrhiza and Shengmai to post-operative patients with obstructive jaundice may effectively decrease the postoperative levels of plasma LPS, ET, TNFα, IL-6 and IL-8. At the same time, Salvia miltiorrhiza and Shengmai may protect renal function by inhibiting inflammatory mediator and improving blood dynamics.
出处
《华西药学杂志》
CAS
CSCD
2003年第1期10-12,共3页
West China Journal of Pharmaceutical Sciences
基金
卫生部科研基金资助课题 (98-1-2 15 )
